Altmetric

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

File Description SizeFormat 
Rucaparib NDA_RevisedManuscript_15Aug2017_clean.pdfAccepted version310.75 kBAdobe PDFView/Open
1-s2.0-S009082581731260X-main.pdfPublished version1.48 MBAdobe PDFView/Open
Title: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Authors: Oza, AM
Tinker, AV
Oaknin, A
Shapira-Frommer, R
McNeish, IA
Swisher, EM
Ray-Coquard, I
Bell-McGuinn, K
Coleman, RL
O'Malley, DM
Leary, A
Chen, L-M
Provencher, D
Ma, L
Brenton, JD
Konecny, GE
Castro, CM
Giordano, H
Maloney, L
Goble, S
Lin, KK
Sun, J
Raponi, M
Rolfe, L
Kristeleit, RS
Item Type: Journal Article
Abstract: OBJECTIVE: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). METHODS: Eligible patients from Study 10 (NCT01482715) and ARIEL2 (NCT01891344) who received a starting dose of oral rucaparib 600mg twice daily (BID) with or without food were included in these analyses. The integrated efficacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation who received at least two prior chemotherapies and were sensitive, resistant, or refractory to platinum-based chemotherapy. The primary endpoint was investigator-assessed confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR) and progression-free survival (PFS). The integrated safety population included patients with HGOC who received at least one dose of rucaparib 600mg BID, irrespective of BRCA1/2 mutation status and prior treatments. RESULTS: In the efficacy population (n=106), ORR was 53.8% (95% confidence interval [CI], 43.8-63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median DOR was 9.2months (95% CI, 6.6-11.6). In the safety population (n=377), the most frequent treatment-emergent adverse events (AEs) were nausea, asthenia/fatigue, vomiting, and anemia/hemoglobin decreased. The most common grade ≥3 treatment-emergent AE was anemia/hemoglobin decreased. Treatment-emergent AEs led to treatment interruption, dose reduction, and treatment discontinuation in 58.6%, 45.9%, and 9.8% of patients, respectively. No treatment-related deaths occurred. CONCLUSIONS: Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile.
Issue Date: 4-Sep-2017
Date of Acceptance: 20-Aug-2017
URI: http://hdl.handle.net/10044/1/53950
DOI: https://dx.doi.org/10.1016/j.ygyno.2017.08.022
ISSN: 0090-8258
Publisher: Elsevier
Start Page: 267
End Page: 275
Journal / Book Title: Gynecologic Oncology
Volume: 147
Issue: 2
Copyright Statement: © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Ovarian carcinoma
PARP inhibitor
Rucaparib
Somatic, germline BRCA mutation
Adult
Aged
Aged, 80 and over
BRCA1 Protein
BRCA2 Protein
Female
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Indoles
Middle Aged
Neoplasm Grading
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
1112 Oncology And Carcinogenesis
1114 Paediatrics And Reproductive Medicine
Oncology & Carcinogenesis
Publication Status: Published
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons